

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliament and Council of 27 October 1998

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Roche Professional Diagnostics
Sandhofer Strasse 116
68305 Mannheim
Germany

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)


Produktname/Product name: **Assay Tip/Assay Cup**

Art.-Nr./Id. No.: 12102137001


Beschreibung/Description: The Assay Tip/Assay Cup is used as an IVD-accessory on the following systems:
E170 module
cobas e 601 module
cobas e 602 module

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 04. Nov. 2013
Roche Diagnostics GmbH
ppa./on behalf of the company


Dr. M. Thein
Head of Quality
Roche Professional Diagnostics

ppa./on behalf of the company


Ralf Zielenski
Head of Quality GPS and RDI
Roche Diagnostics International Ltd

Kontaktadresse/Contact address: Roche Professional Diagnostics
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
68305 Mannheim
Germany
Fax: +49 621/759 1448

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product name: CleanCell M
Cat.-No.: 04880293190
Basic UDI-DI: 761333601330A4
Risk Class: ☒ A ☐ B ☐ C ☐ D

Conformity Route: ☒ Self-Declaration of Conformity (Class A)
☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
☐ Technical Documentation Assessment Class B/C – Annex IX
☐ Technical Documentation Assessment Class D – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates: ☐ EU QM Certificate No.:
☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Notified Body (NB) Name: N/A
NB Address:

NB Ident. No.: N/A

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 24 August 2021


Roche Diagnostics GmbH

ppa./on behalf of the company



A7F0BA9FE91A46A...
Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company



FC5EDEC1054B44C...
Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **Elecsys HBsAg II**

Art.-Nr./Cat. No.: **08814856190**

Beschreibung/Description: Immunologischer In-vitro-Test zur qualitativen Bestimmung von Hepatitis B Oberflächen-Antigen (HBsAg) in Humanserum und -plasma.
Der ElektroChemiLumineszenz ImmunoAssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen.
*Immunoassay for the in vitro qualitative determination of hepatitis B surface antigen (HBsAg) in human serum and plasma.
The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*


auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 16 October 2019

Roche Diagnostics GmbH

ppa./on behalf of the company



Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./on behalf of the company



Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **PreciControl HBsAg II**

Art.-Nr./Cat. No.: **04687876190**

Beschreibung/Description: PreciControl HBsAg II dient zur Qualitätskontrolle der Elecsys HBsAg II und Elecsys HBsAg II Auto Confirm Immunoassays auf Elecsys und **cobas e** Immunoassay-Analysern.

*PreciControl HBsAg II is used for quality control of the Elecsys HBsAg II and Elecsys HBsAg II Auto Confirm immunoassays on the Elecsys and **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 26 August 2020

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:

0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: Elecsys Anti-HCV II

Art.-Nr./Cat. No.: 06368921190

Beschreibung/Description: Der Elecsys Anti-HCV II Test ist ein diagnostischer In-vitro-Test für den qualitativen Nachweis von Antikörpern gegen Hepatitis-C-Virus (HCV) in Humanserum und -plasma.
Der ElektroChemiLumineszenz ImmunoAssay "ECLIA" ist zur Durchführung an Elecsys und **cobas e** Immunoassay-Systemen vorgesehen.
The Elecsys Anti-HCV II assay is an in vitro diagnostic test for the qualitative detection of antibodies to hepatitis C virus (HCV) in human serum and plasma.
*The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 21 August 2018

Roche Diagnostics GmbH

ppa./on behalf of the company

ppa. Dr. Beate Bonefeld


Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./on behalf of the company

i.V. Stefan Grigarczik



Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **PreciControl Anti-HCV**

Art.-Nr./Cat. No.: **03290379190**

Beschreibung/Description: PreciControl Anti-HCV dient zur Qualitätskontrolle des Anti-HCV II Immunoassays an Elecsys und **cobas e** Immunoassay-Systemen.
*PreciControl Anti-HCV is used for quality control of the Anti-HCV II immunoassay on the Elecsys and **cobas e** immunoassay analyzers.*


auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 29 June 2018

Roche Diagnostics GmbH

ppa./on behalf of the company



Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./on behalf of the company

i.V. Dr. Manfred Böhm



Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **Elecsys HIV combi PT**

Art.-Nr./Cat. No.: **08924163190**
08924180190

Beschreibung/Description: Immunologischer In-vitro-Test zur qualitativen Bestimmung von HIV-1 p24-Antigen und Antikörper gegen HIV-1, einschließlich Gruppe O, und HIV-2 in Humanserum und -plasma. Der ElektroChemilumineszenz ImmunoAssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen.

Immunoassay for the in vitro qualitative determination of HIV-1 p24 antigen and antibodies to HIV-1, including group O, and HIV-2 in human serum and plasma.

*The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*


auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 29 May 2020

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:

A45CC19E27A04F3...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address:* Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)

as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: **PreciControl HIV Gen II**

Art.-Nr./Cat. No.: **06924107190**

Beschreibung/Description: PreciControl HIV Gen II dient zur Qualitätskontrolle von Elecsys HIV combi PT, Elecsys HIV Duo und Elecsys HIV Ag Immunoassays an Elecsys und **cobas e** Immunoassay-Systemen.
PreciControl HIV Gen II is used for quality control of the Elecsys HIV combi PT, Elecsys HIV Duo and Elecsys HIV Ag immunoassays on the Elecsys and cobas e immunoassay analyzers.


auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 31 March 2017

Roche Diagnostics GmbH

ppa./on behalf of the company



Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./on behalf of the company



Dr. Peter Martin
Senior Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product name: PreClean M
Cat.-No.: 03004899190
Basic UDI-DI: 761333601258AM
Risk Class: ☒ A ☐ B ☐ C ☐ D

Conformity Route: ☒ Self-Declaration of Conformity (Class A)
☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
☐ Technical Documentation Assessment Class B/C – Annex IX
☐ Technical Documentation Assessment Class D – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates: ☐ EU QM Certificate No.:
☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Notified Body (NB) Name: N/A
NB Address:

NB Ident. No.: N/A

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 24 August 2021

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:
 **Ralf Zielenski**
A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:
 **Stefan Scheib**
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product name: ProbeWash M
Cat.-No.: 03005712190
Basic UDI-DI: 761333601259AP
Risk Class: ☒ A ☐ B ☐ C ☐ D

Conformity Route: ☒ Self-Declaration of Conformity (Class A)
☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
☐ Technical Documentation Assessment Class B/C – Annex IX
☐ Technical Documentation Assessment Class D – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates: ☐ EU QM Certificate No.:
☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Notified Body (NB) Name: N/A
NB Address:

NB Ident. No.: N/A

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 24 August 2021

Roche Diagnostics GmbH

ppa./on behalf of the company

DocuSigned by:

A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product name: ProCell M
Cat.-No.: 04880340190
Basic UDI-DI: 761333601332A8
Risk Class: ☒ A ☐ B ☐ C ☐ D

Conformity Route: ☒ Self-Declaration of Conformity (Class A)
☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)
☐ Technical Documentation Assessment Class B/C – Annex IX
☐ Technical Documentation Assessment Class D – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX
☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX
☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates: ☐ EU QM Certificate No.:
☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Notified Body (NB) Name: N/A
NB Address:

NB Ident. No.: N/A

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 24 August 2021

Roche Diagnostics GmbH


ppa./on behalf of the company

DocuSigned by:

A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./on behalf of the company

DocuSigned by:

FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliament and Council of 27 October 1998

Hersteller/Manufacturer: Roche Diagnostics GmbH

Adresse/Address: Sandhofer Strasse 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/Product name: Elecsys Syphilis

Art.-Nr./Cat. No.: 06923348190

Beschreibung/Description: Immunologischer In-vitro-Test zur qualitativen Bestimmung der Gesamt-Antikörper gegen *Treponema pallidum* in Humanserum und -plasma. Der Test dient als Hilfe bei der Diagnose einer Syphilis-Infektion.
Der ElektroChemiLumineszenz ImmunoAssay "ECLIA" ist zur Durchführung an Elecsys und **cobas e** Immunoassay-Systemen vorgesehen.
Immunoassay for the in vitro qualitative determination of total antibodies to Treponema pallidum in human serum and plasma. The test is intended as an aid in the diagnosis of syphilis infection.
*The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.*


auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.

to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 21 November 2017

Roche Diagnostics GmbH

ppa./on behalf of the company



Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./on behalf of the company

i.V. Dr. Stefan Scheib



Dr. Peter Martin
Senior Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/EC Declaration of Conformity

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliament and Council of 27 October 1998

Hersteller/Manufacturer: Roche Diagnostics GmbH
Adresse/Address: Roche Professional Diagnostics
Sandhofer Straße 116
D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/Product name: **PreciControl Syphilis**

Art.-Nr./Id. No.: **06923364**

Beschreibung/Description: PreciControl Syphilis dient zur Qualitätskontrolle des Elecsys Syphilis Immunoassays an Elecsys und **cobas e** Immunoassay-Systemen.
PreciControl Syphilis is used for quality control of the Elecsys Syphilis immunoassay on the Elecsys and cobas e immunoassay analyzers.

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 03.02.2014

Roche Diagnostics GmbH
ppa./on behalf of the company



Dr. M. Thein
Head of Quality
Roche Professional Diagnostics

i. V./on behalf of the company



Dr. C. Fleischer
Head of Quality Control Penzberg
Roche Diagnostics Global Operations

Kontaktadresse/Contact address: Roche Professional Diagnostics
Abt./Dept. Global Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

06923364_PreciControl Syphilis - Ia

Roche Diagnostics GmbH Diagnostics Division

Roche Diagnostics GmbH

Werk Penzberg; Nonnenwald 2; D-82377 Penzberg; Telefon +49-8856-60-0; Telefax +49-8856-60-3896
Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Dr. Ursula Redeker, Sprecherin;
Edgar Vieth - Aufsichtsratsvorsitzender: Dr. Severin Schwan